TNIB Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech,

New Post Public Reply Private Reply Replies (0) Message Board

Oct 11, 2012 at 3:17 PM

[b]TNIB >Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer[/b]

2012-10-11 07:30 ET - News Release

NEW YORK, NY and POTOMAC MD -- (Marketwire) -- 10/11/12

TNI BioTech, Inc. (PINKSHEETS: TNIB), a public company operating in the biotech sector, announced today the signing of an agreement with Pharmaceutical Care Consultants of South Florida, d/b/a Skip's Pharmacy. Under the agreement, Dr. Henry "Skip" Lenz and Phil Giordano will join the company as heads of Quality Control and Quality Assurance for TNIB's pharmaceutical plant in Managua, Nicaragua. Dr. Lenz will be responsible for leading the company's global manufacturing development.

Dr. Lenz will join the company's executive leadership team, and report to Noreen Griffin, CEO and Dr. Eugene Youkilis, President of TNI BioTech, Inc. As the company's Quality Control Officer, Dr. Lenz will be responsible for assuring all manufacturing meets cGMP standards. Dr. Lenz has held senior management positions in quality control, quality assurance and production for several international manufacturers. In addition, Dr. Lenz held senior clinical research pharmacist positions with both domestic and international clinical research groups, including Senior Researcher at Key Pharmaceuticals in charge of the Research Division. Dr. Lenz founded and ran a contract research company producing over 10 patents before being acquired by a mid-sized manufacturing company. Over the last fifteen years Dr. Lenz has set his sights on relieving HIV/AIDS by participating in clinical applications of several novel therapies.

Dr. Lenz is a graduate of The Massachusetts College of Pharmacy and the University of Florida. Currently, he owns Pharmaceutical Care Consultants of South Florida d/b/a Skip's Pharmacy in Boca Raton, Florida with his partner Phil Giordano. Skip's Pharmacy is dedicated to providing the highest quality and optimum pharmaceutical care through its unique ability to formulate and compound drugs specifically to meet patient's needs. Skip's Pharmacy has been the leading outlet for the supply of LDN for over ten years.

Noreen Griffin, TNI BioTech, Inc.'s CEO, noted the company's hiring of Dr. Lenz and his partners continues to reflect TNI BioTech's commitment to deliver a quality product and to become a world-class leader in innovative therapeutics for patients afflicted with autoimmune and infectious diseases such as cancer and HIV/AIDS.

Dr. Lenz stated, "I was pleased to see that TNIB was taking the manufacturing and distribution of IRT-103 (LDN) seriously. It is important that IRT-103 (LDN), a treatment that has done so much good for some any people, be available at a quality and a price that benefits everyone."

About TNI Biotech, Inc.

TNI BioTech, Inc., is a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.

Our proprietary technology, therapies and patents, will be used to treat a wide range of cancers. Our most advanced clinical programs involve immunotherapy that works by isolating a patient's lymphocytes and then incubating them together with Methionine Enkephalin (MENK) in an enriching external incubation system. After incubation the patient's lymphocytes are re-infused back into the patient where they combat and destroy tumor cells.

Even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK as a valuable candidate in the treatment of the following:

Autoimmune states such as rheumatoid arthritis and multiple sclerosis;
As an adjunct to antibiotics in the treatment of infectious diseases;
In cancer patients undergoing chemotherapy, radiation treatments or surgery;
Patients with AIDS, in combination with retroviral drug therapy; and
In wound healing or herpes viral infections.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," "intends," or "expects," used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.

See http://www.tnibiotech.com for more information.

Contact:

Global Investment Media

Phone: 310-353-6277

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

University Highlights Scholars' Impact on Leadership

Navigating the Frontier of Academic Research There's a certain grit to diving headfirst into academia's tricky landscapes, and the University of Phoenix is throwing its cap in the ring with their inaugural President's Award. It's all happening at this virtual jamboree they call the Knowledge Without Boundaries Summit on October 22–23, 2026. They're spotlighting the...

qBraid OS Launching Quantum Computing to New Heights

Paving a New Era for Quantum Computing That quantum computing isn't just about flashy algorithms anymore. It's about weaving together some downright powerful hardware under a seamless system. Enter qBraid OS, the new kid on the block offering a sprawling interface to drape quantum processors, CPUs, and NVIDIA GPUs over one cohesive operating system. Folks in the thick of...

Knexus Teams with Google Cloud to Boost Public Sector AI

Kicking Off a New Era for AI in Government There's a fresh wind blowing in how government agencies approach artificial intelligence, and it’s got Knexus and Google Cloud’s Gemini initiative written all over it. Set in Vienna, Virginia, the announcement rolls out a heavy-hitting collaboration that might just rewire how public sectors handle data. October 20, 2026,...

LAZ Parking and indiGOtech's Bold EV Charging Move

EV Chargers: The Future Parked Closer? I've been around the block more times than a cabbie in Manhattan rush hour, and let me tell you, when it comes to EVs, folks are still playing catch-up. But here's a kicker—LAZ Parking and indiGOtech have decided they're not gonna wait around. This joint venture of theirs aims to sock some sense into the old condo complex parking...

Supermicro, Nokia, and NVIDIA Collaborate on AI-RAN Edge

AI Drives Evolution in Network Infrastructure Look, the world of networking won't sit still, and Supermicro proves it's got skin in the game by bringing AI right to the network's edge. This time, they're hob-nobbing with Nokia and NVIDIA to see what AI-RAN can really do. If this feels like a sneak peek into the future, well, that’s because it is. These guys are blending...

Florida Poly's Astro: First Flying Police Vehicle Takes Off

Flying Into A New Era of Campus Safety Hold onto your hats, folks, because we're catapulting straight into the future. Florida Polytechnic University just rolled out something straight from sci-fi flicks—a flying police car. Yep, you heard right. They've dubbed it 'Astro,' after that lovable pooch from the Jetsons. Pioneering Advanced Air Mobility The Florida...

Plaid Eyes Data Horizons; Acorns Embraces Gen Z

Fintech's Next Frontier: Plaid's Vision You ever get the feeling some folks see further down the road than others? That's Plaid CTO Will Robinson, chatting up the NYSE folks at Money20/20. The man’s got his eyes on what he calls "making sense" of financial data—no small feat in our swamped digital world. Plaid ain't some penny stock operation, either. This is an $8...

Glint: Lovense's New Era in Intimacy Tech

From Thrill to Touch: The Glint Debut Screw the traditional remote control for sex toys! Lovense is straight up flipping the script with Glint. This isn't about adding more buttons or connecting another app. We're talking about a butt plug that lets your partner's thrust set the whole vibe. Forget fumbling with phones in the heat of the moment—this toy syncs your...

Shadeform Debuts Flex VMs, Revolutionizing GPU Utilization

GPU Utilization Gets a New Spin with Flex VMs Folks, listen up: Shadeform just fired up something slick with its new Flex VMs. And, let me tell you, in today's market where GPU capacity is vanishing faster than free hotcakes on a Sunday morning, this might well be a game changer. Shadeform’s the name to remember, teaming up data center veterans with peeps who need to...

SKF Q3 2026: Margins Edge Up Amid Strategic Shifts

Cracking Open SKF's Latest Quarterly Numbers Ever seen a company limber up for a big change while tiptoeing through a minefield? That’s SKF for you in this third quarter ending September 2026. Imagine them trying to juggle a spinning platter of growth, strategic separation, and robust margins, all while balancing a wobbly market. A Close Look at Q3's Financial Feats...